MedPath

Zenith® Fenestrated+ Clinical Study

Not Applicable
Recruiting
Conditions
Extent IV Thoracoabdominal
Aortic Aneurysm, Abdominal
Juxtarenal Aortic Aneurysm
Pararenal Aneurysm
Interventions
Device: Zenith Fenestrated+ Endovascular Graft in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System and Unibody2
Registration Number
NCT04875429
Lead Sponsor
Cook Research Incorporated
Brief Summary

The Zenith® Fenestrated+ Endovascular Graft Clinical Study will assess the safety and effectiveness of the Zenith® Fenestrated+ Endovascular Graft (ZFEN+) in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System (BeGraft) and Unibody2 for the treatment of patients with aortic aneurysms involving one or more of the major visceral arteries.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
102
Inclusion Criteria

Not provided

Exclusion Criteria
  1. Age < 18 years
  2. Life expectancy < 2 years
  3. Pregnant, breast-feeding, or planning to become pregnant within 60 months
  4. Inability or refusal to give informed consent by the patient or legally authorized representative
  5. Unwilling or unable to comply with the follow-up schedule, required clinical assessments, and imaging
  6. Simultaneous participation in another investigation study, unless the patient is at least 30 days beyond the primary endpoint of any previous study

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Aortic abdominal aneurysmZenith Fenestrated+ Endovascular Graft in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System and Unibody2-
Primary Outcome Measures
NameTimeMethod
Composite measure of device technical success and procedural safety30 days post procedure

Percent of patients with device technical success and freedom from procedural safety events in the following criteria:

1. Device technical success which includes delivery, deployment, and withdrawal of the device without the need for unanticipated corrective intervention), and

2. Freedom from the following procedural safety events: rupture, aneurysm-related mortality, permanent paraplegia, new onset renal failure requiring dialysis, bowel ischemia requiring surgery, and disabling stroke

Composite measure of freedom from aneurysm-related mortality and clinically significant reintervention12 months post procedure

Percent of patients meeting the following criteria:

1. Freedom from aneurysm-related mortality (death from aneurysm rupture, death from any cause occurring within 30 days of procedure or secondary intervention or device or procedure related death) and

2. Freedom from clinically significant reintervention (including open surgery to restore blood flow or restore bodily function, any device related intervention requiring hospitalization, placement of an additional endovascular graft component(s), placement of a stent(s) as indicated for loss of or for having inadequate fixation, seal or patency)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (31)

University of Alabama Birmingham Hospital

🇺🇸

Birmingham, Alabama, United States

University of Southern California

🇺🇸

Los Angeles, California, United States

Stanford Hospitals and Clinics

🇺🇸

Stanford, California, United States

Tampa General Hospital

🇺🇸

Tampa, Florida, United States

Emory University Hospital

🇺🇸

Atlanta, Georgia, United States

Northwestern Memorial Hospital

🇺🇸

Chicago, Illinois, United States

Loyola University Medical Center

🇺🇸

Maywood, Illinois, United States

UC San Diego

🇺🇸

La Jolla, California, United States

Endeavor Health

🇺🇸

Naperville, Illinois, United States

Methodist Hospital of Indiana

🇺🇸

Indianapolis, Indiana, United States

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

Beth Israel Deaconess Medical Center

🇺🇸

Boston, Massachusetts, United States

Medstar Washington Hospital Center

🇺🇸

Washington, District of Columbia, United States

University of Florida Shands Hospital

🇺🇸

Gainesville, Florida, United States

New York University Langone Medical Center

🇺🇸

New York, New York, United States

University of Massachusetts

🇺🇸

Worcester, Massachusetts, United States

University of Michigan Health System

🇺🇸

Ann Arbor, Michigan, United States

Mayo Clinic

🇺🇸

Rochester, Minnesota, United States

Barnes Jewish Hospital

🇺🇸

Saint Louis, Missouri, United States

Dartmouth-Hitchcock Medical Center

🇺🇸

Lebanon, New Hampshire, United States

Columbia University Irving Medical Center/NY Presbyterian Hospital

🇺🇸

New York, New York, United States

University of North Carolina at Chapel Hill

🇺🇸

Chapel Hill, North Carolina, United States

Cleveland Clinic Foundation

🇺🇸

Cleveland, Ohio, United States

Hospital of the University of Pennsylvania

🇺🇸

Philadelphia, Pennsylvania, United States

University of Pittsburgh Medical Center

🇺🇸

Pittsburgh, Pennsylvania, United States

Medical University of South Carolina

🇺🇸

Charleston, South Carolina, United States

Holston Valley Hospital

🇺🇸

Kingsport, Tennessee, United States

Ut Southwestern

🇺🇸

Dallas, Texas, United States

Memorial Hermann Texas Medical Center/UT Health

🇺🇸

Houston, Texas, United States

Carilion Roanoke Memorial Hospital

🇺🇸

Roanoke, Virginia, United States

St Thomas' Hospital

🇬🇧

London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath